US009408856B2

(12) **United States Patent**
Schwartz et al.

(10) **Patent No.: US 9,408,856 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **TOPICAL STEROIDAL FORMULATIONS**

(71) Applicant: **Temple University—Of The Commonwealth System of Higher Education**, Philadelphia, PA (US)

(72) Inventors: **Arthur G Schwartz**, Perkasie, PA (US); **John R Williams**, Merion Station, PA (US)

(73) Assignee: **TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION**, Philadelphia, PA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 302 days.

(21) Appl. No.: **13/799,895**

(22) Filed: **Mar. 13, 2013**

(65) **Prior Publication Data**

US 2013/0196959 A1 Aug. 1, 2013

Related U.S. Application Data

(62) Division of application No. 12/494,928, filed on Jun. 30, 2009, now Pat. No. 8,431,555.

(60) Provisional application No. 61/076,784, filed on Jun. 30, 2008.

(51) **Int. Cl.**

A61K 31/566	(2006.01)
A61K 31/5685	(2006.01)
A61K 9/00	(2006.01)
A61K 9/06	(2006.01)
A61K 31/573	(2006.01)
A61K 47/26	(2006.01)
A61K 47/10	(2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/5685*** (2013.01); ***A61K 9/0014*** (2013.01); ***A61K 9/06*** (2013.01); ***A61K 31/566*** (2013.01); ***A61K 31/573*** (2013.01); ***A61K 47/10*** (2013.01); ***A61K 47/26*** (2013.01)

(58) **Field of Classification Search**
CPC A61K 31/56; A61K 31/566
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,898,694	A	2/1990	Schwartz et al.	
5,001,119	A	3/1991	Schwartz et al.	
5,028,631	A	7/1991	Schwartz et al.	
5,157,031	A	10/1992	Schwartz et al.	514/177
5,656,621	A	8/1997	Schwartz et al.	514/177
5,696,106	A	12/1997	Schwartz et al.	514/177
5,700,793	A	12/1997	Schwartz et al.	514/177
5,709,878	A	1/1998	Rosenbaum et al.	
5,714,481	A	2/1998	Schwartz et al.	
5,744,462	A	4/1998	Schwartz et al.	
5,804,576	A	9/1998	Schwartz et al.	514/177
5,869,090	A	2/1999	Rosenbaum et al.	
7,271,234	B2	9/2007	Kohn et al.	
2003/0083231	A1	5/2003	Ahlem et al.	
2003/0157157	A1	8/2003	Luo et al.	
2004/0019026	A1	1/2004	Schwartz	
2005/0020552	A1	1/2005	Aschkenasy et al.	514/177

(Continued)

FOREIGN PATENT DOCUMENTS

WO	WO 2006/036484	4/2006	A61K 45/06

OTHER PUBLICATIONS

Hastings, et al., "Dehydroepiandrosterone and two structural analogs inhibit 12-O-tetradecanoylphorbol-13-acetate stimulation of prostaglandin E2 content in mouse skin", *Carcinogenesis*, Jun. 1988: 9(6): 1099-102 (Abstract only).

Janjikhel, et al., "Improved Bioavailability of a Poorly Water Soluble Drug by Nanosizing", *American Association of Pharmaceutical Scientists Journal*, 4 (S1), abstract only (2002).

Malik, et al., "A Novel Dehydroepiandrosterone Analog Improves Functional Recovery in a Rat Traumatic Brain Injury Model", *Journal of Neurotrauma*, 20(5): 463-477 (2003).

(Continued)

Primary Examiner — Wu-Cheng Winston Shen
Assistant Examiner — Christopher R Stone
(74) *Attorney, Agent, or Firm* — Drinker Biddle & Reath LLP

(57) **ABSTRACT**

The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.

Formula I



Formula II



22 Claims, No Drawings